Ethics and compliance

Learn about our Code of Conduct

Our board of directors and senior leadership enacted a Code of Conduct as the foundation of how we work responsibly with integrity. Though the Code of Conduct is available in multiple languages, all employees follow the same high ethical standards. The chief compliance officer oversees the Ethics and Compliance program, with oversight from the chief executive officer and Governance and Compliance Committee of the board of directors.

Code of Conduct resources

Code of Conduct handbook

Conduct Line website

Code of Conduct contact information

You can report an issue by emailing Ethics and Compliance at GMB-CFN-EthicsandC@carefusion.com or by calling the Conduct Line.

The Conduct Line is available 24 hours a day, seven days a week for employees and third parties to confidentially and, if desired, anonymously raise issues about the business conduct of our company and its employees.

Using the Conduct Line is optional and secondary to the other reporting channels on the Quick Resources List in the Code.

In the United States

Outside of the United States

Consult the international phone numbers list to find the direct number. Multilingual representatives are available; however, you may need to wait briefly for an appropriate representative.

If the phone numbers on the international list do not work, call one of these:

  • European,* Middle Eastern and African economic areas tel: 41.21.556.3166
  • Latin American economic area tel: 55.11.4615.9322
  • Asia-Pacific economic area tel: 86.21.6036.9333

Note that in the European Economic Area,* as well as in Switzerland and Canada, the Conduct Line can be confidentially used only for concerns regarding SOX-related matters.**

Submitting written reports

In addition to using the Conduct Line, you may submit written concerns or reports of possible violations regarding accounting, auditing, internal controls or financial reporting to the chairperson of the Audit Committee or board of directors at:

BD
c/o Chief Compliance Officer
3750 Torrey View Court
San Diego, CA 92130

Conflict minerals policy compliance

In August 2012, the U.S. Securities and Exchange Commission (SEC) adopted a final rule to implement reporting and disclosure related to "conflict minerals" as directed by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010. BD is committed to conducting business with suppliers that adhere to the highest ethical standards and comply with laws and regulations applicable to their business.

Learn more about our commitment to this act.

Unique device identifier compliance

On September 24, 2013, the United States Food and Drug Administration (FDA) released a final rule requiring that most medical devices distributed in the United States carry a unique device identifier (UDI). The UDI system facilitates medical device identification, traceability and tracking through distribution and use. Due to this new regulation, BD is transitioning to the new UDI regulation to comply with the FDA deadline dates.

Learn more about our commitment to this ruling.